Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial

Phase 4

Completed

Conditions: Autoimmune Hepatitis

Interventions: Drug: Chloroquine diphosphate
Drug: prednisone
Drug: azathioprine

First Posted Date: 2015-06-04

Last Posted Date: 2017-02-15

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 57

Registration Number: NCT02463331

Study of Treatment Response on IgG4 Related Disease (IgG4RD)

Phase 2

Conditions: Autoimmune Disease

Interventions: Drug: Prednisone and Mycophenolate mofetil
Drug: Prednisone

First Posted Date: 2015-06-01

Last Posted Date: 2017-01-24

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 60

Registration Number: NCT02458196

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis

Phase 3

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Cyclophosphamide injections
Drug: Tacrolimus capsules
Drug: Prednisone

First Posted Date: 2015-05-29

Last Posted Date: 2024-11-01

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 314

Registration Number: NCT02457221

Locations: 🇨🇳
Site CN00005, Dalian, Liaoning, China
🇨🇳
Site CN00045, Liuzhou, Guangxi, China
🇨🇳
Site CN00025, Nanjing, Jiangsu, China

and more 32 locations

Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Docetaxel
Drug: Prednisone
Drug: Enzalutamide

First Posted Date: 2015-05-25

Last Posted Date: 2024-05-30

Lead Sponsor: Santa Chiara Hospital

Target Recruit Count: 246

Registration Number: NCT02453009

Locations: 🇮🇹
Santa Chiara Hospital, Trento, Italy

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: Lab Work
Drug: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)
Drug: Certolizumab pegol (CDP870, tradename Cimzia)
Drug: Hydroxychloroquine
Drug: Sulfasalazine
Drug: Medrol
Drug: Prednisone
Drug: Triamcinolone
Drug: Naproxen
Drug: Leflunomide
Drug: Methotrexate
Drug: humira

First Posted Date: 2015-05-22

Last Posted Date: 2024-07-10

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 32

Registration Number: NCT02451748

Locations: 🇺🇸
Outpatient Care Center, Chicago, Illinois, United States

Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma

Phase 3

Recruiting

Conditions: Follicular Lymphoma

Interventions: Radiation: Consolidation involved-site radiotherapy (ISRT)
Radiation: Consolidation involved-field radiotherapy (IFRT)
Drug: cyclophosphamide
Drug: doxorubicin
Drug: vincristine
Drug: prednisone

First Posted Date: 2015-05-20

Last Posted Date: 2015-12-14

Lead Sponsor: Wuhan University

Target Recruit Count: 120

Registration Number: NCT02449252

Locations: 🇨🇳
DiDeng, Wuhan, Hubei, China

Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma

Phase 3

Recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Radiation: Consolidation involved-field radiotherapy (IFRT)
Radiation: Consolidation involved-site radiotherapy (ISRT)
Drug: cyclophosphamide
Drug: doxorubicin
Drug: vincristine
Drug: prednisone

First Posted Date: 2015-05-20

Last Posted Date: 2015-12-14

Lead Sponsor: Wuhan University

Target Recruit Count: 160

Registration Number: NCT02449265

Locations: 🇨🇳
DiDeng, Wuhan, Hubei, China

The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

Phase 3

Recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Radiation: Consolidation involved-site radiotherapy (ISRT)
Radiation: Consolidation involved-field radiotherapy (IFRT)
Drug: cyclophosphamide
Drug: doxorubicin
Drug: vincristine
Drug: prednisone

First Posted Date: 2015-05-20

Last Posted Date: 2015-12-14

Lead Sponsor: Wuhan University

Target Recruit Count: 120

Registration Number: NCT02449278

Locations: 🇨🇳
DiDeng, Wuhan, Hubei, China

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Phase 3

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Pegylated liposomal doxorubicin
Drug: Doxorubicin
Drug: Rituximab
Drug: Cyclophophamide
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2015-04-29

Last Posted Date: 2015-11-18

Lead Sponsor: Wenqi Jiang

Target Recruit Count: 216

Registration Number: NCT02428751

Locations: 🇨🇳
Nanfang Hospital of Southern Medical Unversity, Guangzhou, Guangdong, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 4 locations

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
Recurrent Ph-Like Acute Lymphoblastic Leukemia
Refractory Ph-Like Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dasatinib
Drug: Dexamethasone
Drug: Doxorubicin
Other: Laboratory Biomarker Analysis
Drug: Leucovorin
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Prednisone
Biological: Rituximab
Drug: Ruxolitinib Phosphate
Drug: Vincristine

First Posted Date: 2015-04-20

Last Posted Date: 2024-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT02420717

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy